| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000043291 |
| Receipt No. | R000049423 |
| Scientific Title | Influence of nonalcoholic fatty liver disease on locally advanced breast cancer: a retrospective cohort study |
| Date of disclosure of the study information | 2021/02/11 |
| Last modified on | 2021/02/09 (Ver. 1) |
| Basic information | ||
| Public title | Influence of nonalcoholic fatty liver disease on locally advanced breast cancer: a
retrospective cohort study |
|
| Acronym | Influence of NAFLD on LABC | |
| Scientific Title | Influence of nonalcoholic fatty liver disease on locally advanced breast cancer: a
retrospective cohort study |
|
| Scientific Title:Acronym | Influence of NAFLD on LABC: a
retrospective cohort study |
|
| Region |
|
|
| Condition | ||
| Condition | locally advanced breast cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the association between NAFLD and the prognosis and morbidity of patients with LABC |
| Basic objectives2 | Others |
| Basic objectives -Others | Association with prognosis |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Recurrence-free survival(RFS) |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | stage III breast cancer who underwent radical surgery | |||
| Key exclusion criteria | inflammatory breast cancer, concurrent malignancies, or previous malignant diseases within 5 years | |||
| Target sample size | 44 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Hyogo Prefectural Amagasaki General Medical Center | ||||||
| Division name | Breast surgery | ||||||
| Zip code | 6608550 | ||||||
| Address | 2-17-77, Higashi naniwa cho, Amagasaki | ||||||
| TEL | 06-6480-7000 | ||||||
| tajit.mutsu@gmail.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Hyogo Prefectural Amagasaki General Medical Center | ||||||
| Division name | Breast surgery | ||||||
| Zip code | 6608550 | ||||||
| Address | 2-17-77, Higashi naniwa cho, Amagasaki | ||||||
| TEL | 06-6480-7000 | ||||||
| Homepage URL | |||||||
| tajit.mutsu@gmail.com | |||||||
| Sponsor | |
| Institute | Hyogo Prefectural Amagasaki General Medical Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Self funding |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Hyogo Prefectural Amagasaki General Medical Center |
| Address | 2-17-77, Higashi naniwa cho, Amagasaki |
| Tel | 0664807000 |
| agmc.irb@gmail.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 44 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | RFS was defined as the duration from the date of biopsy to the date of death or distant recurrence, local recurrence, or diagnosis of secondary cancer. Survival confirmation was the last visit to our hospital. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049423 |